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OBJECTIVES This research was designed to assess the effect of type 2 diabetes mellitus (T2DM) on
myocardial glucose utilization in patients with heart failure secondary to coronary artery
disease.
BACKGROUND Patients with T2DM and coronary artery disease have an increased morbidity and mortality
compared with patients with coronary artery disease without diabetes that may relate to a
reduction in the ability of the myocardium to utilize glucose.
METHODS Myocardial blood flow and glucose utilization were assessed during a hyperinsulinemic clamp
by 18F-flurodeoxyglucose and positron emission tomography in 54 patients (19 with T2DM)
with multivessel coronary artery disease and heart failure. In a subgroup of 18 patients,
myocardial biopsies were obtained during coronary bypass surgery to assess glucose trans-
porter (GLUT4) distribution and protein concentration, and compared with myocardium
from transplant donor hearts.
RESULTS Myocardial blood flow was similar in patients without diabetes and those with T2DM.
Myocardial glucose utilization was lower in patients with T2DM (0.34  0.16 vs. 0.47 
0.24 mol·min1·g1, p  0.0002) despite comparable plasma insulin concentrations and a
higher blood glucose concentration. Extraction of glucose by the myocardium was reduced in
patients with T2DM (7.1  3.1% vs. 13.5  5.2%, p  0.01). Myocardial GLUT4 protein
was similar in patients with and without T2DM (p  0.75).
CONCLUSIONS Patients with coronary artery disease and heart failure exhibit myocardial insulin resistance,
and this is greater in those with T2DM. This may limit the ability of the myocardium in
patients with T2DM to withstand ischemia and may contribute to the increased cardiovas-
cular morbidity and mortality in such patients. (J Am Coll Cardiol 2006;48:2225–31)
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.06.078© 2006 by the American College of Cardiology Foundation
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(ype 2 diabetes mellitus (T2DM) is associated with an
ncreased risk of coronary artery disease (CAD). In addi-
ion, after an acute coronary syndrome or myocardial infarc-
ion, patients with T2DM have a disproportionately higher
isk of serious complications and death, (1–3), which
uggests that the hearts of these patients are less tolerant to
schemia.
See page 2232
In the fasting, post-absorptive state, a minority of energy
roduction in the human heart is derived from glucose
xidation. After eating, the release of a number of hormones
ncluding insulin influences myocardial metabolism (4).
nsulin facilitates myocardium glucose utilization, largely by
eans of the insulin-dependent translocation of the glucose
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ccepted June 8, 2006.ransporter (GLUT4) from the intracellular pool to the
lasma membrane (5). By decreasing plasma free fatty acids
FFA), insulin has also a profound indirect effect on
yocardial lipid utilization, which is linearly related to FFA
oncentration in the bloodstream (6).
Ischemia results in increased myocardial glucose utiliza-
ion (MGU) derived both from glycogen breakdown and
ncreased utilization of circulating glucose, and such a
etabolic shift is mediated by the action of insulin (7).
ncreased translocation of GLUT4 from intracellular vesi-
les to the plasma membrane has been demonstrated in
odels of low flow ischemia and in stunned myocardium
8,9). As knockout mice lacking GLUT4 show a severely
mpaired response to ischemia, the shift to a glycolytic
etabolism is thought to be an adaptive response for
yocardial survival.
Insulin resistance is a central feature of T2DM, but the
nsulin sensitivity of the heart in patients with TD2M with
AD remains the subject of debate. Studies using positron
mission tomography (PET) with 18F-flurodeoxyglucose
FDG) have reported reduced MGU during hyperinsulin-
mia in patients with T2DM (10). Others have not found
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T2DM and Myocardial Glucose Utilization December 5, 2006:2225–31yocardial insulin resistance in patients with T2DM (11),
lthough myocardial insulin resistance has been found in
atients with hypertension, heart failure, and myocardial
ypertrophy (12–14).
In this study, we investigated the combined effect of
2DM and heart failure secondary to CAD on myocardial
lucose during hyperinsulinemia using FDG-PET. In ad-
ition, we measured GLUT4 protein in myocardial biopsies
btained at cardiac surgery to gain insight into the molec-
lar mechanism underlying abnormal MGU.
ETHODS
atients. This was a single-center study of 54 patients
mean age 63  13 years) with heart failure secondary to
ultivessel CAD who were undergoing assessment of
yocardial viability with a view to coronary artery bypass
rafting (CABG). Of the 54 patients, 19 had T2DM and
5 were non-diabetic patients (Table 1). Patients with
nsulin-treated diabetes, a recent history of myocardial
nfarction, unstable angina, or decompensated heart failure
in the preceding 2 months) were excluded. Viability was
efined by preserved utilization of the glucose analogue
DG in at least 6 of the 16 left ventricular (LV) segments
15). The reversibility of LV dysfunction in a segment with
Table 1. The Demographic Characteristics of
Patient Demographics
Age (yrs)
Heart rate (beats/min)
Systolic blood pressure (mm Hg)
Diastolic blood pressure (mm Hg)
Rate-pressure product (mm Hg·beats/min)
Weight (kg)
BSA (m2)
BMI (kg·m2)
NYHA functional class
LVEF (%)
WMSI
Values expressed as mean  SD.
Abbreviations and Acronyms
CABG  coronary artery bypass grafting
CAD  coronary artery disease
FDG  18F-flurodeoxyglucose
FFA  free fatty acid
GLUT4  glucose transporter 4
LV  left ventricle/ventricular
MBF  myocardial blood flow
MGU  myocardial glucose utilization
PET  positron emission tomography
PPAR  peroxisome proliferator-activated receptor
PTF  perfusable tissue fraction
ROI  region of interest
TACs  time-activity curves
T2DM  type 2 diabetes mellitusBMI  body mass index; BSA  body surface area; LVEF  l
Association; T2DM  type 2 diabetes mellitus; WMSI  wall mreserved viability (hibernation) was confirmed by improved
ontractile function at 6-month post-operative echocardi-
graphy. In a subgroup of 18 patients (6 with T2DM) with
iable anterior LV wall myocardium, biopsies were taken at
he time of CABG.
tudy protocol. All medication was withheld on the day of
he study. Patients were asked to avoid activities that might
recipitate angina for 24 h before the study and to fast from
vernight before attending for the study that was com-
enced between 9 AM and 10 AM. All subjects were asked to
onsume a diet containing at least 200 g of carbohydrate for
days before the study.
The Local Research Ethics Committees of the Queen
lizabeth Hospital, Birmingham, and the Hammersmith
ospital, London, approved the protocol. Radiation expo-
ure was licensed by the United Kingdom Administration of
adioactive Substances Advisory Committee. All patients
ave fully informed written consent.
ssessment of regional LV function. Global and regional
V function was assessed by resting 2-dimensional echo-
ardiography using conventional views (parasternal long-
nd short-axis, apical 2- and 4-chamber views). Regional
all motion was scored the using the standard 16-segment
odel by 2 experienced observers who were blinded to the
linical data. Regional wall motion was scored using a
-point grading scale: 1  normal, 2  mildly hypokinetic,
 severely hypokinetic, 4  akinetic, and 5  dyskinetic.
egments with a wall motion score 3 were considered
ysfunctional.
ET: regional myocardial perfusion. The PET studies
ere performed using an ECAT 931-08/12 15-slice scanner
CTI/Siemens, Knoxville, Tennessee) after an overnight
ast and abstinence from caffeine-containing beverages for at
east 24 h. All emission and transmission sinograms were
econstructed using a Hanning filter with a cut-off fre-
uency of 0.5 maximum. A 20-min transmission scan was
erformed to facilitate subsequent attenuation correction of
ll emission scans, and the blood pool was imaged by
nhalation of tracer amounts of 15O-labeled carbon monox-
de (C15O) as previously described (16).
4 Patients Studied
Diabetes
 35)
T2DM
(n  19) p Value
.3  8.8 61.6  9.6 NS
.1  4.4 71.2  5.2 NS
4  5.8 142  6.2 NS
.8  6.2 87.3  8.7 NS
4  680 10,098  728 NS
7  12 82  15 NS
9  0.17 1.94  0.20 NS
.9  3.2 27.7  4.2 NS
3  0.58 2.36  0.30 NS
.7  11.0 28.2  11.2 NS
7  0.72 2.24  0.67 NSthe 5
No
(n
62
68
13
84
9,22
7
1.8
25
2.3
26
2.3eft ventricular ejection fraction; NYHA  New York Heart
otion score index.
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December 5, 2006:2225–31 T2DM and Myocardial Glucose UtilizationAfter allowing for the decay of 15O radioactivity, resting
yocardial blood flow (MBF) was measured using oxygen-
5-labelled water (H2
15O, 700 to 900 MBq), injected
ntravenously over 20 s at a rate of 10 ml/min with flushing
or a further 2 min. The following scanning protocol was
sed: 14  5 s, 3  10 s, 3  20 s, and 4  30 s, for a total
canning time of 310 s.
yperinsulinemic glucose clamp. A hyperinsulinemic
lamp was performed to determine whole body insulin
ensitivity and to provide a standardized metabolic milieu
or the measurement of MGU. The subjects were placed in
he semirecumbent position, and a cannula inserted into a
orearm vein 20 min before drawing venous blood into
hilled tubes, that were centrifuged immediately at 4°C and
he plasma separated for immediate determination of glu-
ose concentration (by the glucose oxidase technique, YSI
300 STAT PLUS, Yellow Spring, Ohio). The remaining
lasma was frozen in 2 aliquots at 20°C for subsequent
nsulin and FFA assay. Plasma insulin was assayed by a
pecific radioimmunoassay and FFA measured in duplicate
sing a spectrophotometric assay (Wako, Neuss, Germany).
A second cannula was inserted into a superficial vein on
he dorsum of the left hand that was arterialized using a
eating pad set at 50°C to facilitate blood sampling during
euglycemic insulin clamp. A primed infusion of insulin
as initially infused at a rate of 160 U·min1·m2 (4 times
he final rate) for 4 min, then 80 U·min1·m2 (twice the
nal rate) for 3 min and thereafter continued until the end
f the study at a constant rate of 40 U·min1·m2. Four
inutes after commencing the insulin infusion, at the same
ime as reducing the rate to 80 U·min1·m2, an infusion
f 20% D-glucose was commenced at a rate of 0.015
g·kg1·min1. Samples of arterialized blood were then
aken every 5 min through the other indwelling cannula to
onitor blood glucose concentration, and the infusion rate
f D-glucose was increased as required to maintain eugly-
emia. Whole-body glucose utilization (M) was computed
uring the steady-state phase of the clamp. A further blood
ample was taken to determine plasma insulin and FFA
oncentration 90  10 min after commencing insulin.
egional MGU. The MGU was measured during the
quilibrium phase of the previously described hyperinsuline-
ic clamp. After at least 90 min of hyperinsulinemia, 185
Bq of FDG were injected over a 2-min period and a
6-frame dynamic PET scan acquired (1  30 s [back-
round]; 12 10 s; 3 20 s; 4 30 s; 5 60 s; 4 150 s;
 300 s; 2  600 s). The acquired sinograms were
orrected for attenuation and reconstructed as previously
escribed. In brief, blood volume quantitative images were
alculated using the C15O emission data, corrected for the
ecay, and used to define regions of interest (ROIs) that
ere projected onto the dynamic H2
15O data to generate
ime-activity curves (TACs) for each ROI. The average of
hese curves was then used as the arterial input function to
alculate MBF. Additional ROIs were positioned on the
econstructed short-axis FDG images and used to define the w6 LV segments and MGU computed from fitted tissue
ACs using a linearized approach.
Myocardial glucose use was corrected for perfusable tissue
raction (PTF), an index of tissue viability derived from the
2
15O scan, in order to account for the presence of fibrotic
issue (17). Myocardial viability was defined as regional
GU (PTF-corrected) 0.25 mol/min/g as previously
escribed (18). Serum glucose and FFA were measured at
aseline after an 8-h fasting period and immediately before
njection of FDG (median of 76 min from commencement
f dextrose and insulin infusions).
yocardial biopsies and immunoblotting. In a subgroup
f 18 patients (6 with T2DM) who proceeded to CABG, a
ru-cut biopsy was obtained from the region between the
rst diagonal branch and the mid-portion of the left anterior
escending coronary artery shortly after the institution of
ardiopulmonary bypass and before cooling. The biopsy was
mmediately frozen in liquid nitrogen and stored at 70°C
ending analysis. Control biopsies were taken from trans-
lant donor hearts before implantation (n  7). The
rimary antibody was a rabbit anti-peptide polyclonal anti-
ody to GLUT4 (AB1346) (Chemicon, Temecula, Califor-
ia). The secondary antibody was a donkey anti-rabbit
lkaline phosphatase (Perbio, Hampton, New Hampshire).
abeled blots were scanned by transmission using a Hewlett
ackard Deskscan (Palo Alto, California) and the band
ensity was quantified using Sigma Gel software package
Sigma Chemical Co., St. Louis, Missouri). The results
ere normalized using the density of the myosin band
200 kDa) identified using a Coomassie blue-stained
inigel matching each immunoblot using a sample com-
on to all experiments, and the measurements were ex-
ressed as arbitrary units (AU).
tatistical analysis. Data are presented as mean values 
D and comparison made using paired or unpaired Student
tests. Differences between proportions were compared
sing the chi-square test with Yates’ correction. A p value
0.05 was considered statistically significant.
ESULTS
he demographic characteristics of the patients studied are
iven in Table 1. Of the 19 T2DM patients, 12 were
eceiving oral hypoglycemic agents (sulphonylurea alone in
, combined with metformin in 4), and 7 were treated by
iet alone. There was a history of previous myocardial
nfarction in 13 (36%) of those without diabetes and 6
31%) of the T2DM subjects. There were no significant
ifferences in weight or body mass index between the
atients with and without diabetes, and symptoms (New
ork Heart Association functional class), LV ejection frac-
ion, and regional wall motion indexes were similar in the 2
roups.
In the patients with T2DM, the fasting plasma glucose
as significantly higher and plasma insulin concentration
as double that of the patients without T2DM, although
t
D
b
h
g
f
g
0
d
1
P
e
p
t
a
M
w
d
w

d
h
p
t

(
C
p
m
t
r
n
I
c
e
G
f
f
A
s
A
D
T
a
M
s
G
f
p
t
F
p
a
p
r
r
t
s mell
2228 Dutka et al. JACC Vol. 48, No. 11, 2006
T2DM and Myocardial Glucose Utilization December 5, 2006:2225–31he plasma FFA concentration was similar (Table 2).
uring the equilibrium phase of the clamp, immediately
efore the injection of FDG, plasma insulin concentration
ad increased to similar levels in the 2 groups, and plasma
lucose remained different and comparable to that during
asting (Table 2). The reduction in FFA concentration was
reater in those without diabetes (mean fall 0.75  0.37 vs.
.67  0.35 mEq·ml1, p  0.05). Whole body glucose
isposal (M) was lower in patients with T2DM (2.24 
.61 vs. 3.74  1.53 mg·kg1·min1, p  0.05).
ET tissue characterization and MGU. There was no
vidence for a greater degree of myocardial fibrosis in
atients with T2DM as assessed by PTF (an index of the
issue viability derived from the H2
15O scan) or by regional
nalysis of wall motion at echocardiography (Table 3).
yocardial blood flow was similar in patients with and
ithout T2DM (Table 3), and the distribution of MBF
uring the clamp was similar in the patients with and
ithout diabetes (Fig. 1A).
Global MGU was lower in patients with T2DM (0.34
0.16 vs. 0.47  0.24 mol·min1·g1, p  0.0002)
espite comparable plasma insulin concentrations and a
igher blood glucose concentration. In both T2DM
atients and non-diabetic patients, MGU was lower than
hat of healthy volunteers from our database (0.61  0.07
mol·min1·g1) (19).
In the subjects with T2DM, MGU was globally reduced
p  0.0001 vs. subjects without diabetes) (Fig. 1B).
ombining the blood glucose concentration and MBF
rovides an estimate of the delivery of glucose to the
yocytes, and from the resultant MGU, a glucose extrac-
Table 2. Plasma Glucose, Insulin, and Free Fa
Equilibrium Phase of the Hyperinsulinemic Cl
Fasting blood results
Blood glucose (mmol·l1)
Plasma insulin (pmol·l1)
Free fatty acid (mEq·ml)
Equilibration phase of the clamp before FDG injecti
Blood glucose (mmol·l1)
Plasma insulin (pmol·l1)
Free fatty acid (mEq·ml)
M value
Values expressed as mean  SD.
FDG  18F-flurodeoxyglucose; T2DM  type 2 diabete
Table 3. MBF and MGU, Tissue Fraction, an
Glucose Tolerance and Those With T2DM
Resting MBF (ml·min1·g1)
Blood glucose · MBF product (mmol·ml·min1·g1)
MGU (mol·min1·g1)
Tissue fraction (alpha)
WMSI
Glucose extraction (%)Values expressed as mean  SD.
MBF  myocardial blood flow; MGU  myocardial glucose uion fraction can be derived (Table 3). A highly significant
eduction in glucose extraction by the myocardium was
oted in the myocardium of patients with T2DM (Fig. 1C).
mmunoblots. In order to estimate GLUT4 in the myo-
ardium, Western blots were performed on the proteins
xtracted from the myocardial biopsies. The amount of
LUT4 protein was significantly lower in myocardium
rom the patients with heart failure compared with samples
rom donor myocardium (0.93  0.49 AU vs. 1.63  0.30
U, p  0.002). Glucose transporter 4 expression was
imilar in diabetic and non-diabetic patients (0.88  0.43
U vs. 0.96  0.54 AU, p  0.75) (Fig. 2).
ISCUSSION
his study shows that in patients with heart failure second-
ry to CAD, T2DM contributes to a further decrease in
GU despite the higher blood glucose concentration and
imilar MBF. Compared with controls from donor hearts,
LUT4 protein content was lower in patients with heart
ailure and CAD regardless of the presence of T2DM. In
atients with T2DM, the reduced ability of the myocardium
o extract glucose is associated with limited suppression of
FA and whole-body insulin resistance.
The ability to increase glycolysis is an important com-
ensatory mechanism to protect the heart against ischemia
nd infarction (20,21). In previous studies, the hearts of
atients with CAD and post-ischemic remodeling have a
educed ability to utilize glucose (13,14), with a direct
elationship between contractile function (LV ejection frac-
ion) and myocardial insulin-mediated glucose utilization
cid Levels at Baseline and During the
No Diabetes T2DM p Value
5.0  0.6 8.0  3.6 0.001
33  34 66  76 0.001
0.98  0.36 0.94  0.26 NS
4.87  0.85 7.5  1.64 0.01
351  270 367  282 NS
0.20  0.14 0.31  0.26 0.01
3.74  1.53 2.24  1.61 0.05
itus.
ucose Extraction in Patients With Normal
No Diabetes T2DM p Value
0.84  0.29 0.87  0.37 NS
4.03  1.72 5.30  2.41 0.05
0.47  0.24 0.34  0.16 0.01
0.54  0.12 0.57  0.13 NS
2.27  1.02 2.28  1.04 NS
13.5  5.2 7.1  3.1 0.01tty A
amp
ond Gltilization; other abbreviations as in Table 1.
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December 5, 2006:2225–31 T2DM and Myocardial Glucose Utilization10). Insulin resistance is a hallmark of T2DM, and al-
hough myocardial insulin resistance may not be a feature of
ncomplicated T2DM, such patients are at increased risk of
AD and have a worse outcome than non-diabetic patients
fter an ischemic event. A number of studies report slight
mpairment of insulin-stimulated MGU in T2DM without
AD (22,23), whereas others demonstrate normal FDG
ccumulation in the myocardium of patients with T2DM
uring physiological hyperinsulinemia (11).
The present study was designed to explore the effect of
eart failure secondary to CAD and T2DM on the ability of
igure 1. The distribution of myocardial blood flow (MBF) (A), myocar-
ial glucose utilization (MGU) (B), and glucose extraction (C) during the
uglycemic hyperinsulinemic clamp in the patients with and without type
diabetes mellitus (T2DM). Ant  anterior regions of the left ventricle;
P  inferoposterior regions of the left ventricle; Lat  lateral regions of
he left ventricle.
igure 2. Anti-glucose transporter 4 immunoblot (top) with matching co
lus in donor myocardium. Immunoblots from diabetic patients are den
ensitometric quantification of the glucose transporter 4 immunoblot was norm
oomassie blue stained gel.he heart to utilize glucose. Our findings confirm that
atients with treated heart failure and CAD are insulin
esistant, and that T2DM confers additional impairment of
yocardial insulin sensitivity. This reduction in MGU in
atients with heart failure, CAD, and T2DM is not a
eflection of lower perfusion because resting MBF was
imilar in diabetic and non-diabetic subjects. In patients
ith CAD, abnormalities of myocardial metabolism extend
eyond regions with contractile dysfunction, and insulin
ensitivity is globally impaired. As myocyte survival during
schemia is dependent on the generation of high-energy
hosphates from glucose, the shift toward anaerobic metab-
lism is a critical adaptive reaction. The association of CAD
nd T2DM results in a greater degree of myocardial insulin
esistance, and may contribute to the increased morbidity
nd mortality associated with myocardial ischemia in these
atients. The present study suggests that patients with
2DM and heart failure secondary to CAD exhibit a
reater degree of myocardial insulin resistance.
The main myocyte glucose carrier is GLUT4, and during
asting it is primarily found within intracellular vesicles.
nsulin induces a rapid translocation of GLUT4 to the
arcolemma, thereby increasing the cell capacity to take up
lucose. Abnormalities of GLUT4 have been demonstrated
n hypertrophic cardiac remodeling and the diabetic heart in
umans and animal models (24). The reduction of GLUT4
n such conditions is believed to limit the ability of the heart
ells to import glucose and to withstand and recover from
schemia. The reduction of GLUT4 protein found in our
tudy is in accord with these previous studies. The lower
GU during hyperinsulinemia in patients with T2DM,
espite similar levels of myocardial GLUT4 protein, sug-
ests that GLUT4 expression is not rate-limiting for MGU.
nother factor limiting MGU is the higher plasma FFA
oncentration in T2DM (25). In humans, a highly negative
orrelation between FFA and net glucose disposal was
bserved in a large study of more than 500 Europeans
uring a glucose clamp (26). Using nuclear magnetic reso-
ance spectroscopy, a 50% reduction in insulin-stimulated
hole-body glucose metabolism has been reported if FFA is
levated before commencing the hyperinsulinemic euglyce-
ic clamp (27). In a previous study, we reported that FFAs
ere equally suppressed during an insulin clamp in diabetic
nd non-diabetic subjects (10); this was not the case in the
ie blue stained gel (bottom) from patients with hibernating myocardium
D. Molecular weight standards are shown in the left lane of the gel.omass
otedalized for myosin heavy chain content using the band at 200 kDa on the
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T2DM and Myocardial Glucose Utilization December 5, 2006:2225–31resent study of patients with heart failure, CAD, and
2DM. The reduced suppression of circulating FFA, de-
pite resting insulinemia, may, therefore, contribute to the
educed ability of the heart to utilize glucose. These findings
re of interest in view of the new peroxisome proliferator-
ctivated receptor (PPAR) agonists of the thiazolidine-
iones class, which have been shown to improve post-
eceptor insulin signaling and insulin sensitivity.
Recent studies have increased our understanding of the
ffects of selective PPAR- ligands (glitazones) with ther-
peutic effects that extend beyond their use as insulin
ensitizers including beneficial effects in conditions associ-
ted with ischemia/reperfusion and inflammation (28,29).
urrently, these drugs are used in the therapy of patients
ith T2DM without heart failure. As previously discussed,
hese patients have a significantly higher incidence of acute
yocardial infarction, and the finding that glitazones reduce
yocardial infarct size when given before the onset of an
schemic episode (at least in animals) may be clinically
mportant. A number of studies have reported that glita-
ones exert potent anti-inflammatory effects in animal
odels of acute and chronic inflammation although the
echanisms underlying the anti-ischemic effects of these
gents are not entirely clear.
The administration of systemic glucose-insulin-potassium
ay protect the myocardium and promote adequate cardiac
nd hemodynamic performance that would improve recov-
ry after ischemia. Trials that have examined the role of
lucose-insulin-potassium in cardiac surgery have been
mall, open-label, and involved a wide variety of regimens.
ecently, a trial of glucose-insulin-potassium or placebo
uring cardiac surgery has reported an improvement in early
ost-operative cardiovascular performance, reduced ino-
rope requirement, and demonstrated less evidence of sig-
ificant myocardial injury in non-diabetic patients under-
oing CABG (29).
tudy limitations. Hyperglycemia, in addition to its
nown toxic cellular effects, increases the activity of induc-
ble nitric oxide synthase and promotes inflammation while,
n contrast, insulin exerts anti-inflammatory and antiapop-
otic effects. The precise benefit of insulin administered
ither alone to achieve tight glucose control or as a compo-
ent of glucose-insulin-potassium therapy merits further
esearch. In addition, GLUT4-null mice have been reported
o increase MGU in response to insulin in a manner similar
o control animals, although with a markedly delayed
esponse. Although we aimed to assess the GLUT1 protein
evel in the myocardial samples, this analysis was hindered
y the contamination of the samples by high amounts of
LUT1 from non-cardiac sources (erythrocytes).
onclusions. Patients with T2DM and heart failure sec-
ndary to CAD have lower MGU compared with those
ithout diabetes despite higher plasma glucose and insulin
oncentrations. The reduced ability of the myocardium to
xtract glucose in these patients does not appear to be
econdary to a reduction in GLUT4 availability.cknowledgments
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